Heron Therapeutics Inc. (NASDAQ:HRTX) shares saw unusually-strong trading volume on Wednesday . Approximately 5,200,192 shares changed hands during mid-day trading, an increase of 457% from the previous session’s volume of 933,020 shares.The stock last traded at $20.83 and had previously closed at $19.86.

A number of analysts have weighed in on HRTX shares. Jefferies Group restated a “buy” rating and issued a $46.00 target price on shares of Heron Therapeutics in a research report on Wednesday, July 27th. Cowen and Company restated a “buy” rating on shares of Heron Therapeutics in a research report on Saturday, July 9th. Leerink Swann restated a “buy” rating on shares of Heron Therapeutics in a research report on Monday, June 27th. Cantor Fitzgerald restated a “buy” rating and issued a $41.00 target price on shares of Heron Therapeutics in a research report on Friday, June 24th. Finally, Brean Capital restated a “buy” rating and issued a $55.00 target price on shares of Heron Therapeutics in a research report on Friday, May 6th. One research analyst has rated the stock with a sell rating, nine have given a buy rating and one has assigned a strong buy rating to the company. Heron Therapeutics presently has an average rating of “Buy” and an average price target of $50.30.

The firm has a 50-day moving average price of $17.70 and a 200 day moving average price of $18.85.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings data on Monday, August 8th. The biotechnology company reported ($1.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.96) by $0.21. On average, equities analysts forecast that Heron Therapeutics Inc. will post ($3.82) EPS for the current fiscal year.

Other hedge funds recently made changes to their positions in the company. California State Teachers Retirement System increased its stake in shares of Heron Therapeutics by 1.9% in the fourth quarter. California State Teachers Retirement System now owns 54,211 shares of the biotechnology company’s stock worth $1,447,000 after buying an additional 1,000 shares during the last quarter. GAM Holding AG increased its stake in shares of Heron Therapeutics by 28.9% in the fourth quarter. GAM Holding AG now owns 41,900 shares of the biotechnology company’s stock worth $1,119,000 after buying an additional 9,400 shares during the last quarter. Russell Frank Co increased its stake in shares of Heron Therapeutics by 46.9% in the fourth quarter. Russell Frank Co now owns 48,830 shares of the biotechnology company’s stock worth $1,369,000 after buying an additional 15,585 shares during the last quarter. Swiss National Bank bought a new stake in shares of Heron Therapeutics during the fourth quarter worth about $1,100,000. Finally, California Public Employees Retirement System increased its stake in shares of Heron Therapeutics by 863.8% in the fourth quarter. California Public Employees Retirement System now owns 90,600 shares of the biotechnology company’s stock worth $2,419,000 after buying an additional 81,200 shares during the last quarter.

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.